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LETTERS
BRL 43694: A Novel
Antiemetic to Prevent
Nausea and Vomiting
Induced by Chemotherapy
High-dose metoclopramide has
been widely used for the reduction of
nausea and vomiting induced by can-
cer chemotherapy. Accumulated evi-
dence suggests that the action of high-
dose metoclopramide is related to the
antagonism of 5-hydroxytryptamine-3
receptors (5-HT3) at peripheral sites
and possibly at central sites (7,2).
BRL 43694' was developed recently
as a selective 5-HT3 receptor an-
tagonist. On the basis of a study in
healthy volunteers, we initiated a pi-
lot study of BRL 43694 in patients
receiving strongly emetogenic cancer
chemotherapy.2
From August 1987 to February
1988 we treated eight female and 12
male ambulatory tumor patients hav-
ing a median age of 45 years (range,
24-65) with BRL 43694 administered
as a 30-minute infusion 1 hour af-
ter the administration of the cyto-
statics. The first seven patients were
treated with a dose of 40 fig/V.g body
weight. Thereafter, we increased the
dose to 100 Mg/kg- Thirteen patients
received cisplatin >50 mg/m2 as their
first course of chemotherapy; seven
patients were established vomiters
(these patients had experienced >5
vomiting episodes during a previous
course of chemotherapy despite con-
ventional antiemetic treatment with
a combination of high-dose meto-
clopramide, methylprednisolone, and
flunitrazepam). All patients were hos-
pitalized to receive their chemother-
apy and antiemetic drugs. A research
nurse recorded the number of vom-
iting episodes, the volume of erne-
sis, and the duration of nausea, retch-
ing, and vomiting. The antiemetic
effect was assessed semiquantitatively
with the following scoring system as
recorded during the previous hour no
nausea, retching, or vomiting = 0;
nausea = 1; retching = 2; vomiting
(single episode) = 3; and vomiting
(multiple episodes) = 4. After each
hour the patient was given a score,
and the values for the 24-hour period
were added together. The antiemetic
efficacy was defined according to the
24-hour score as follows: complete re-
sponse = 0; major partial response =
1-6; minor partial response = 7-12;
and failure >12.
The results are summarized in ta-
ble 1. Nine patients (45%) had no
vomiting episode; four patients (20%)
had 1-2 episodes; six patients (30%)
had 3-5 episodes; and only one pa-
tient with anticipatory vomiting ex-
perienced 11 vomiting episodes over
24 hours following the administra-
tion of the chemotherapy. Accord-
ing to our assessment, 70% of the
patients were completely or partially
protected from nausea and vom-
iting. The efficacy was better in
the group of chemotherapy-naive pa-
tients, with 85% of the patients experi-
encing protection. Sixty percent of the
patients experienced moderate vom-
iting (1-5 episodes) 24-48 hours
after chemotherapy, and 40%
experienced vomiting 48-72 hours
after the chemotherapy. There was
no suggestion that the higher dose
of BRL 43694 offered greater pro-
tection. Thirteen patients received a
second course and seven patients a
third course of BRL 43694 on subse-
quent courses of chemotherapy. The
antiemetic efficacy was maintained.
No consistent adverse events were at-
tributable to BRL 43694.
BRL 43694 is one of several
new 5-HT3 receptor antagonists cur-
rently undergoing clinical evaluation.
Our results in 20 patients receiving
highly emetogenic cancer chemother-
apy suggest that BRL 43694 is a
highly active antiemetic. We ex-
pect that without effective antiemetic
treatment all of our patients would
have experienced severe protracted
nausea and vomiting. Overall, 70%
derived significant benefit, and the
'Tentatively designated Graiiisetron pending
approval.
2Data on file. Beecham Pharmaceuticals, Re-
search Division, Harlow, England.
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Table 1. Antiemetic activity of BRL 43694
Number of patients
Median score (range)
No. of patients (%) showing
Complete response
Major partial response
Minor partial response
Failure
Median No. of
vomiting episodes
(range)
Median volume of
emesis in mL
(range)
Tnfal
1 IHal
20
6(0-31)
8(40)
2(10)
4(20)
6(30)
1 (0-11)
15(0-1180)
No prior
therapy
13
3(0-15)
6(46)
2(15)
3(24)
2(15)
0(0-5)
0(0-410)
Prior
therapy
7
15(0-31)
2(28)
0(0)
1 (14)
4(58)
3(0-11)
355 (0-1180)
success rate was even higher in
chemotherapy-naive patients (85%).
Furthermore, the antiemetic activ-
ity of BRL 43694 was maintained
upon retreatment Finally, the essen-
tial lack of adverse effects makes
the drug a very attractive antiemetic.
Randomized trials comparing BRL
43694 to standard antiemetic therapy
(high-dose metoclopramide plus dex-
amethasone) in chemotherapy-naive
patients are currently under way to es-
tablish the full potential of BRL 43694
as a novel antiemetic drug.
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